CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Bortezomib +2 moredrug
Likely dose
Bortezomib 1.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00703664
NCT00703664Phase 2Completed
CompareCT.gov

Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas

National Cancer Institute (NCI)·interventional·Posted Jun 23, 2008·Updated Aug 7, 2018

In Brief

A Phase 2 clinical trial evaluating Bortezomib, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Mantle Cell Lymphoma and Recurrent Non-Hodgkin Lymphoma. Completed, enrolled 65 participants across 12 sites.

Detailed Summary

This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2008
Enrollment StartJul 9, 2008
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 18.0 years ago

Interventions

Bortezomibdrug

Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.

Laboratory Biomarker Analysisother

Correlative studies

Vorinostatdrug

Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.